SageView Advisory Group
LENZ icon

SageView Advisory Group’s LENZ Therapeutics LENZ Stock Holding History

SageView Advisory Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7
Closed -$112 – 2505
2025
Q4 		$112 Buy
+7
New +$204 ﹤0.01% 2535

Other funds holding LENZ

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Alpha Wave Global
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

SageView Advisory Group's LENZ Position: Q1 2026 in Review

SageView Advisory Group sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 7 shares — an estimated $112 sold.

SageView Advisory Group first reported a position in LENZ in Q4 2025 and held it in 1 quarter. The position peaked at $112 in Q4 2025. 146 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • SageView Advisory Group reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 7 LENZ Therapeutics shares in Q1 2026, an estimated $112.
  • SageView Advisory Group first reported a position in LENZ Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's LENZ Therapeutics position peaked at $112 in Q4 2025.
  • 146 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.